Abiopharma

🔍 McBee Brannin (Executive)

Company: CoreWeave, Inc. (CRWV)

Report Date: 2026-04-27

Detailed Transactions and Holdings:

• Acquired 33,350 shares of Class A Common Stock (Direct)
  Date: 2026-04-27 | Code: C | equity_swap_involved: 0 | shares_owned_after: 33,350.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,667 shares of Class A Common Stock at $105.6104 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,683.00 | transaction_form_type: 4 | Footnotes: F3, F4, F2
• Sold 3,683 shares of Class A Common Stock at $106.57 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 27,000.00 | transaction_form_type: 4 | Footnotes: F3, F5, F2
• Sold 9,242 shares of Class A Common Stock at $107.4854 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 17,758.00 | transaction_form_type: 4 | Footnotes: F3, F6, F2
• Sold 1,889 shares of Class A Common Stock at $108.6159 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,869.00 | transaction_form_type: 4 | Footnotes: F3, F7, F2
• Sold 1,486 shares of Class A Common Stock at $109.5086 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,383.00 | transaction_form_type: 4 | Footnotes: F3, F8, F2
• Sold 4,850 shares of Class A Common Stock at $110.7696 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,533.00 | transaction_form_type: 4 | Footnotes: F3, F9, F2
• Sold 7,845 shares of Class A Common Stock at $111.426 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,688.00 | transaction_form_type: 4 | Footnotes: F3, F10, F2
• Sold 1,688 shares of Class A Common Stock at $112.1269 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F11, F2
• Acquired 12,500 shares of Class A Common Stock (Direct)
  Date: 2026-04-27 | Code: C | equity_swap_involved: 0 | shares_owned_after: 12,500.00 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 1,000 shares of Class A Common Stock at $105.6104 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 11,500.00 | transaction_form_type: 4 | Footnotes: F3, F4, F12
• Sold 1,380 shares of Class A Common Stock at $106.57 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,120.00 | transaction_form_type: 4 | Footnotes: F3, F5, F12
• Sold 3,464 shares of Class A Common Stock at $107.4853 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,656.00 | transaction_form_type: 4 | Footnotes: F3, F6, F12
• Sold 708 shares of Class A Common Stock at $108.6154 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,948.00 | transaction_form_type: 4 | Footnotes: F3, F7, F12
• Sold 557 shares of Class A Common Stock at $109.5082 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,391.00 | transaction_form_type: 4 | Footnotes: F3, F8, F12
• Sold 1,818 shares of Class A Common Stock at $110.7694 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 3,573.00 | transaction_form_type: 4 | Footnotes: F3, F9, F12
• Sold 2,941 shares of Class A Common Stock at $111.4261 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 632.00 | transaction_form_type: 4 | Footnotes: F3, F10, F12
• Sold 632 shares of Class A Common Stock at $112.1265 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F11, F12
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-27 | Code: H | nature_of_ownership: Canis Major SM Trust | shares_owned_after: 54,000.00 | Footnotes: F13
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-27 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,800.00 | Footnotes: F14
• Sold 33,350 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: C | equity_swap_involved: 0 | shares_owned_after: 3,917,227.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 12,500 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: C | equity_swap_involved: 0 | shares_owned_after: 561,205.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F12
• Holds 324,000 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: H | shares_owned_after: 324,000.00 | Footnotes: F1, F1, F1, F15
• Holds 108,600 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: H | shares_owned_after: 108,600.00 | Footnotes: F1, F1, F1, F16
• Holds 1,582,773 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: H | shares_owned_after: 1,582,773.00 | Footnotes: F1, F1, F1, F2
• Holds 122,000 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: H | shares_owned_after: 122,000.00 | Footnotes: F1, F1, F1, F17
• Holds 263,795 shares of Class B Common Stock (Derivative)
  Date: 2026-04-27 | Code: H | shares_owned_after: 263,795.00 | Footnotes: F1, F1, F1, F12

Footnotes:

• F1: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
• F2: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person is the sole trustee and beneficiary.
• F3: The reported transaction represents a sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2025.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.97, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.02 to $107.01, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.02 to $108.01, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.02 to $108.93, inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $109.995, inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.03 to $111.02, inclusive.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.03 to $112.02, inclusive.
• F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.03 to $112.76, inclusive.
• F12: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person's spouse is the sole beneficiary and trustee.
• F13: The reported securities are directly held by the Canis Major SM Trust (the "Canis Trust"), an irrevocable trust with a third-party trustee, of which the reporting person's minor child is beneficiary. The reporting person has the power to remove and replace the Canis Trust's trustee.
• F14: The reported securities are directly held of record by the reporting person's child.
• F15: The reported securities are directly held by the Canis Major 2024 Irrevocable Trust LLC of which the reporting person serves as manager.
• F16: The reported securities are directly held by the Canis Major 2025 Family Trust LLC, of which the reporting person serves as manager.
• F17: The reported securities are directly held by the Canis Minor 2025 Family Trust LLC, of which the reporting person serves as manager.
• REMARKS: This Form 4 is Part 2 of 2 for this reporting person. Transactions by the reporting person are continued on this Part 2.